At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 808 enrolled
Drug / intervention
mRNA-1893 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas
In Brief
A Phase 2 clinical trial evaluating mRNA-1893 and Placebo for Zika Virus. Completed, enrolled 808 participants across 11 sites in 2 countries.
Detailed Summary
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsZika Virus
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartJun 2021
First PostedJun 2021
Primary CompletionJul 2024
TodayJul 2026
First PostedJun 8, 2021
Enrollment StartJun 7, 2021
Primary CompletionJul 26, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.1 years ago
Interventions
mRNA-1893biological
Solution for injection
Placebobiological
0.9% sodium chloride solution for injection